Post-therapy planar imaging predicts Lutathera response in NETs

Wednesday, December 2 | 8:00 a.m.-9:00 a.m. | W1-SSNMMI05-3 | Room S405  

Whole-body retention measured on post-therapy planar imaging predicts treatment response in patients with neuroendocrine tumors (NETs) receiving lutetium-177 (Lu-177) DOTATATE (Lutathera), according to a presentation in this session. 

Ashley Neal, a medical student at the University of Kentucky College of Medicine, and colleagues conducted a retrospective analysis of Lutathera-treated patients who had post-therapy planar imaging, pretreatment anatomic imaging, and at least six months of follow-up. The primary endpoint compared partial response (PR) versus stable or progressive disease (SD/PD) by RECIST 1.1 criteria. 

Twenty-two patients were included in the response-adjudicated cohort (PR, n = 10; SD/PD, n = 12), with 11 patients contributing 34 treatment cycles to the retention-complete cohort. Across cycles 1 through 4, PR patients showed consistently lower planar retention than SD/PD patients. In pooled cycle-level analysis, median WB retention was significantly lower for PR than SD/PD (12.7% versus 18.3%, p = 0.007). Cycle 1 retention yielded an exploratory AUC of 0.77 for predicting PR versus SD/PD. Percent change in retention at cycle 3 and the overall retention slope across all four cycles each significantly predicted favorable response (p = 0.025 and p = 0.02). 

Lutathera dosimetry via SPECT/CT can assess absorbed dose but requires resources not universally available, the researchers noted. 

"Post-therapy planar imaging may provide accessible response-related information after Lutathera and could help identify patients more likely to benefit from therapy," Neal and colleagues wrote.  

Check out this Wednesday morning session to learn more. 

 

 

Page 1 of 2
Next Page